Mathematical modelling and data science company Physiomics plc (AIM: PYC) announced on Monday that it has been awarded an additional contract by Numab Therapeutics, an existing client.
The project involves Pharmacokinetic-Pharmacodynamic (PKPD) modelling to support Numab's oncology asset entering clinical trials, aiding in dose and scheduling decisions.
Dr Peter Sargent, CEO, expressed enthusiasm about the opportunity to support Numab through the preclinical stages into clinical trials. This project, coupled with the one announced in August 2023, reflects the ongoing collaborative relationship and support provided by Physiomics.
Physiomics leverages advanced PKPD and QSP modelling, along with deep biology expertise, to assist biotech and pharma companies in streamlining drug development. The company's data-driven approach aims to de-risk decision making and optimise research design across discovery, pre-clinical, and clinical studies.
With a focus on deriving insights from relevant data, Physiomics has contributed to over 100 commercial projects, 50 targets, and 75 drugs. Notable clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and CRUK.
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
Oncosure introduces Rapid Cancer Screening Test
Bayer and NextRNA collaborate on LncRNA-targeting therapeutics
GSK welcomes Delaware Supreme Court review of Zantac litigation
Fusion Antibodies expands collaboration with US National Cancer Institute
Telix Pharmaceuticals submits TLX101-CDx NDA to US FDA
Astellas initiates Phase 3 study for fezolinetant in breast cancer patients
Cantargia updates clinical trial timelines for nadunolimab
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation